KURZPROTOKOLL
Neobil AIO-HEP-0120

Öffentlicher Titel	Phase II Studie zu Bintrafusp Alfa bei resezierbarem Gallengangskarzinom
Wissenschaftl. Titel	Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL)
Kurztitel	Neobil AIO-HEP-0120
Studienart	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, einarmig, Investigator Initiated Trial (IIT)
Studienphase	Phase II
Erkrankung	Verdauung: Gallengangs-/Gallenblasenkrebs (maligne biliäre Tumoren): neoadjuvant
Einschlusskriterien	- Written informed consent granted prior to initiation of any study-specific screening procedures - Biliary tract cancer, confirmed by histopathology, cytopathology is not sufficient - Resectable disease limited to the liver assessed by an interdisciplinary tumor board involving a hepatobiliary surgeon - Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up - Age >= 18 years - Performance status ECOG 0-1 - Normal organ and bone marrow function defined as: o Hematopoetic: absolute neutrophil count >=1,500/mm3, platelet count >= 100,000/mm3, o Hemoglobin >=9 g/dL o Normal international normalized ratio (INR), PT <= 1.5 x ULN and activated partial thromboplastin time (aPTT) <= 1.5 x ULN o Hepatic: AST <=5 x ULN, ALT <= 5 x ULN, and bilirubin <= 3.0 x ULN o Renal: Creatinine level <=1.5 x ULN or estimated creatinine clearance >= 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method) - Special medical conditions and comorbidities: o Maximum Child Pugh stage A in patients with cirrhosis o HIV: stable on ART for at least 4 weeks, no documented evidence of multi-drug resistance, viral load of < 400 copies/mL and CD4+ T-cells <= 350 cells/µL o HBV infection: participant on a stable dose of antiviral therapy, HBV viral load below the limit of quantification. - Women of childbearing potential must have a negative serum or highly sensitive urine pregnancy test performed within 7 days prior to the first dose of IMP - Women of childbearing potential (WOCBP) must use HIGHLY EFFECTIVE method(s) of contraception to avoid pregnancy for the duration of study treatment and further 2 months after the last dose of IMP
Ausschlusskriterien	- Metastatic disease - Prior surgery, systemic therapy, radiation therapy, chemoradiation, transarterial chemoembolisation (TACE), Radiofrequency ablation (RFA) or selective intraarterial Radiotherapy (SIRT) for treatment of CCA. NOTE: Laparoscopy for diagnostic procedures is allowed - Drug or alcohol addiction, medical or psychological condition that may interfere with the patient´s participation in the study - Participation in another clinical trial with any investigational study drug (whatever the use, curative, prophylactic or diagnostic intent) within 30 days prior to enrollment - Pregnancy or breast feeding women - Regulatory and ethical criteria: Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG]. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]

- IMMUNOSUPRESSANTS: "Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses <= 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)."
- AUTOIMMUNE DISEASE: "Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible."
- PREVIOUS MALIGNANT DISEASE: within the last 3 years except for a. superficial/non-invasive bladder cancer, or basal or squamous cell carcinoma in situ treated with curative intent; b. endoscopically resected GI cancers limited to the mucosal layer without recurrence in > 1 year
- INFECTIONS: "Active infection requiring systemic therapy. "
- VACCINATION: has received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted
- HYPERSENSITIIVTY TO BINTRAFUSP ALFA: "Known severe hypersensitivity [Grade >= 3 NCI CTCAE 5.0]) to investigational product or any component in its formulations, any history of anaphylaxis, or recent, within 5 months, history of uncontrollable asthma
- CARDIOVASCULAR DISEASE: "Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication."
- BLEEDING: "history of bleeding diathesis or recent major bleeding events (i.e. Grade >= 2 bleeding events in the month prior treatment)
- Other severe acute or chronic medical conditions: "including drug-induced interstitial lung disease (ILD) or participant has had a history of drug-induced pneumonitis that has required oral or IV steroids", and/or other diseases, which in the opinion of the Investigator might impair the participant's tolerance for the study or ability to consistently participate in study procedures

Alter	18 Jahre und älter
Prüfzentren	**Innere Medizin 1** (Geschlossen) Gastroenterologie / Hepatologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Laura Gesell Tel: 069 6301-87769 Laura.Gesell@unimedizin-ffm.de **Universitätsklinikum Frankfurt** (Geschlossen) Medizinische Klinik I, Gastroenterologie/Hepatologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Laura Gesell Tel: 069 6301-87769 Laura.Gesell@unimedizin-ffm.de
Sponsor	AIO-Studien GmbH
Förderer	Merck KGaA
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT04727541 (primäres Register) EudraCT 2020-002605-25